Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC.

导出 LinkOut

翻译打印收藏纠错

第一作者： Xiaoping,Song

第一单位： Department of Pharmaceutical Engineering, School of Chemical Engineering, Northwest University, 229 Taibai North Road, Xi'an, 710069, China.;Biotech. and Biomed. Research Institute, Northwest University, 229 Taibai North Road, Xi'an, 710069, China.

作者： Xiaoping,Song ^[1] ; Lina,Wang ^[1] ; Wei,Tang ^[2] ; Luyao,Yuan ^[3] ; Qingchao,Liu ^[1] ; Jing,Li ^[4] ; Daidi,Fan ^[5]

作者单位： Department of Pharmaceutical Engineering, School of Chemical Engineering, Northwest University, 229 Taibai North Road, Xi'an, 710069, China.;Biotech. and Biomed. Research Institute, Northwest University, 229 Taibai North Road, Xi'an, 710069, China. ^[1] Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266100, China. ^[2] Department of Pharmaceutical Engineering, School of Chemical Engineering, Northwest University, 229 Taibai North Road, Xi'an, 710069, China. ^[3] Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266100, China. lijing_ouc@ouc.edu.cn. ^[4] Department of Pharmaceutical Engineering, School of Chemical Engineering, Northwest University, 229 Taibai North Road, Xi'an, 710069, China. fandaidi@nwu.edu.cn.;Biotech. and Biomed. Research Institute, Northwest University, 229 Taibai North Road, Xi'an, 710069, China. fandaidi@nwu.edu.cn. ^[5]

关键词 Drug Resistance Gefitinib MIG6/STAT3 NSCLC Selumetinib